ReviewDiscover nano2026
A bibliometric analysis of global research trends in tumor microenvironment based nanotherapy.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe tumor microenvironment (TME) is a key factor in cancer progression and drug resistance. Nanomedicine provides a new solution to overcome the limitations of traditional therapies by regulating the TME. With the rapid growth of interdisciplinary research in this field, although there are many descriptive reviews, there is still a lack of a quantitative analysis of long-term research results.
methodsLiterature from the Web of Science database was analyzed to reveal the knowledge structure, the evolution of core concepts, and the future research frontier in this field using VOSviewer, CiteSpace, R-bibliometrix, and R packages.
resultsAnalysis shows that the number of relevant publications has grown rapidly since 2020, and China and the Chinese Academy of Sciences have made outstanding contributions. The dynamic evolution of Subject Categories and Research Themes clarifies the development trajectory of this field from the basic drug delivery theme to the regulation of the complex TME. Keyword co-occurrence analysis identifies core knowledge areas such as ROS-based therapies, metabolic control, immune microenvironment remodeling, and drug delivery. The analysis of cited references and highly cited literature reveals the knowledge base and milestone research that drive the development of this field. The current research frontier and hot spots focus on reshaping the immune microenvironment, novel regulated cell death mechanisms, ROS-based therapies, tumor metabolic reprogramming, combination therapies, and biomimetic/theranostic platforms.
conclusionsThis study reveals the paradigm shift in nanomaterials from passive delivery carriers to multifunctional, bioactive regulators of the TME. Through quantitative analysis, the future development direction of multi-target synergistic intervention is clarified, which provides an important reference for the follow-up research on personalized tumor treatment.
Indexed as
Identifiers
42909804What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.